<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1236">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05145062</url>
  </required_header>
  <id_info>
    <org_study_id>LTS16653</org_study_id>
    <secondary_id>U1111-1256-9430</secondary_id>
    <nct_id>NCT05145062</nct_id>
  </id_info>
  <brief_title>An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Severe Sickle Cell Disease (SCD) and ST-400 in Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant</brief_title>
  <official_title>An Observational Long-term Safety and Efficacy Follow-up Study After Ex-vivo Gene Therapy With BIVV003 in Participants With Severe Sickle Cell Disease (SCD) or With ST-400 in Participants With Transfusion-dependent Beta-thalassemia (TDT) With Autologous Hematopoietic Stem Cell Transplant</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bioverativ, a Sanofi company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objectives:&#xD;
&#xD;
      -Long-term safety of BIVV003 in participants with severe sickle cell disease (SCD) and ST-&#xD;
      400 in participants with transfusion-dependent beta-thalassemia (TDT)&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  Long-term efficacy of the biological treatment effect of BIVV003 in SCD&#xD;
&#xD;
        -  Long-term efficacy of the clinical treatment effect of BIVV003 on SCD-related clinical&#xD;
           events&#xD;
&#xD;
        -  Long-term efficacy of the biological treatment effect of ST-400 in TDT&#xD;
&#xD;
        -  Long-term efficacy of the clinical treatment effect of ST-400 in TDT&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration is up to 15 years of follow-up post BIVV003 and/or ST-400 infusion.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 20, 2021</start_date>
  <completion_date type="Anticipated">March 13, 2043</completion_date>
  <primary_completion_date type="Anticipated">March 13, 2043</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Number of participants with serious adverse events and adverse events related to BIVV003 or ST-400, including new malignancy, new incidence or exacerbation of neurologic or rheumatologic or autoimmune or hematologic disorder, or new incidence of infection potentially related to BIVV003 or ST-400</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Duration from first dose of study medication to death</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin levels</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Long-term change in levels of hemoglobin F, hemoglobin S and total hemoglobin (BIVV003 cohort), long term change in levels of hemoglobin F and total hemoglobin (ST-400 cohort)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemolysis markers</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Long-term change in markers of hemolysis, including reticulocyte count, lactate dehydrogenase, haptoglobin, and serum bilirubin, over time in the BIVV003 cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of severe vaso-occlusive crises</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Percentage of participants with severe vaso-occlusive crises, including acute pain crisis, acute chest syndrome, priapism, and splenic sequestration, in the BIVV003 cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and severity of SCD-related clinical events</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Percentage of participants with SCD-related clinical events (e.g., acute renal failure, acute stroke) in the BIVV003 cohort</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Red blood cell transfusions</measure>
    <time_frame>Up to 15 years</time_frame>
    <description>Number and total volume of red blood transfusions in the BIVV003 and ST-400 cohorts</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">13</enrollment>
  <condition>Blood and Lymphatic Diseases</condition>
  <arm_group>
    <arm_group_label>BIVV003 Cohort</arm_group_label>
    <description>All participants treated in parent and future studies with BIVV003</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ST-400 Cohort</arm_group_label>
    <description>All participants treated in parent studies with ST-400</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BIVV003</intervention_name>
    <description>Solution for intravenous administration</description>
    <arm_group_label>BIVV003 Cohort</arm_group_label>
    <other_name>SAR445136</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ST-400</intervention_name>
    <description>Solution for intravenous administration</description>
    <arm_group_label>ST-400 Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All participants who received BIVV003 in one of the primary parent or future studies or&#xD;
        ST-400 in the ST-400-01 parent study and agree to participate.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Received treatment with BIVV003 or ST-400 in one of the parent studies (ACT16222, ST-&#xD;
             400-01) or any future studies with BIVV003&#xD;
&#xD;
          -  Capable of giving signed informed consent (and if applicable assent)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to comply with study visit schedule or study procedures&#xD;
&#xD;
          -  Any other reason that, in the opinion of the Investigator or Medical Monitor, would&#xD;
             render the participant unsuitable for participation in the study The above information&#xD;
             is not intended to contain all considerations relevant to a potential participation in&#xD;
             a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <verification_date>November 22, 2021</verification_date>
  <study_first_submitted>November 22, 2021</study_first_submitted>
  <study_first_submitted_qc>November 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 6, 2021</study_first_posted>
  <last_update_submitted>November 22, 2021</last_update_submitted>
  <last_update_submitted_qc>November 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Lymphatic Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

